• The study shows that for every additional $1 spent on innovative medicines for pancreatic cancer between 2009 to 2016, there was a reduction in non-medicine spending of $8 to $9  
  • This preliminary study reported that cost of procedures is markedly reduced when budgets are funded towards better pharmacotherapy
  • Non-drug spending represented the majority of patient care costs
  • More effective, better tolerated oral therapies for pancreatic cancer may lead to further reduction of burden on the healthcare system

NEW YORK, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced the results of a health economic outcomes study demonstrating that the therapeutic benefit of increasing the use of  novel medicines is so great that it is driving a decrease in the actual total cost of healthcare. The supporting data from the study were presented at the American Society of Clinical Oncology’s 2020 Gastrointestinal Cancers Symposium (ASCO GI) held on January 23 to 25, 2020 in San Francisco, California.

Health technology assessment programs are increasingly using real-world patient data to assess the effect of new medicines on total cost of care. This study analyzed such data to measure the impact of new pancreatic cancer therapies on other non-therapeutic medical expenditures.

“There is a great need to develop new treatments for pancreatic cancer that balance both efficacy and safety,” said Vincent J. Picozzi, M.D., Director of the Pancreaticobilliary Program at the Floyd & Delores Jones Cancer Institute at the Virginia Mason Medical Center. “The value of advancing treatments is apparent from our total cost of care analysis looking at both medical and pharmacotherapy costs. Our study looked at treatment inflation-adjusted expenses per patient for pancreatic cancer care between 2009 and 2016 and found that for every additional $1 spent on drugs for pancreatic cancer, there was a reduction in non-drug spending of $9.” 

The study showed that between 2009 and 2016, average inflation-adjusted per patient spending on pancreatic cancer care declined from $37,000 to $10,000. Prescription drug spending increased during the same time period from $2,400 to $5,300 per person (inflation adjusted). In effect, for every additional dollar spent on therapies for pancreatic cancer between 2009 to 2016, there was a reduction in non-drug spending of $9.00. 

Total cost of care for patients in this analysis reached a maximum of $280,443 and $312,077 for first and second year of care respectively. Also, between 1997 and 2016 inflation adjusted first- and second-year non-medication charges on pancreatic cancer care averaged $66,999.96 and $105,308.60 respectively.

The study analyzed longitudinal patient-level data from the Medical Expenditure Panel Survey (MEPS, 1996 – 2017). The study evaluated 80 patients who had a diagnosis of pancreatic cancer and available prescription data. Individual age and employment status were accounted for as covariates. Notably, the data revealed that while prescription medicine expenses have increased as part of the total cost of treating patients with pancreatic cancer over the last ten years, the overall healthcare cost of treating pancreatic cancer patients has gone down.

All analyses were performed using R version 3.6.1 on Ubuntu 19.04. Means and standard deviations were computed for the raw and inflation-adjusted total health care costs excluding drug spending. Study averages were computed for the total health care costs, including prescription medicine costs for the period between 2009-2016 which included approval and use of novel treatment approaches such as Abraxane® (nab-paclitaxel), FOLFIRINOX and erlotinib. The prescription medicines expenses, and proportion of healthcare spending were also plotted along with a LOESS curve using the same parameters. All expenditures are adjusted for inflation using 2012 U.S. Dollars.

As a result of this health economic outcomes study, further analysis of a larger, longitudinal set of patient-level data is needed to more fully explore the relationship between spending on medical innovation, and reduction in total cost of patient care, as well as improvements in quality of life.

Details of this study were presented at the American Society of Clinical Oncology’s 2020 Gastrointestinal Cancers Symposium (ASCO GI) held on January 23 to 25, 2020 in San Francisco, California. The poster was presented on Friday, January 24, 2020, from 12:00 PM PT to 1:30 PM PT and 4:30 PM PT to 5:30 PM PT during the Poster Display Session in Poster Hall. The poster is available on our website (www.tymeinc.com/data-publications).

The health economic outcomes poster on pancreatic cancer presented at the ASCO GI Cancer Symposium in San Francisco is as follows:  

Title: An Assessment of the Total Cost of Pancreatic Cancer Using Real-World Evidence

Authors: Vincent J. Picozzi1, Victoria G. Manax2, Kelly Feehan2, Zachary Wintrob3, Michele Korfin4, Giuseppe Del Priore4, Robert Goldberg5

Institutions: Virginia Mason Medical Center, Seattle, WA1, Pancreatic Cancer Action Network, Manhattan Beach, CA2, Roaketin, Inc., Buffalo, NY3, Tyme Technologies, Inc., NY, NY4, Center for Medicine in the Public Interest, NY, NY5

Session Date and Time: Friday, January 24, 2020, 12:00 PM PT – 1:30 PM PT and 4:30 PM PT – 5:30 PM PT
Session Title: Poster Display Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Abstract Number: 773
Poster Number: Board N18

About Advanced Pancreatic Cancer
Advanced pancreatic cancer is a difficult-to-treat cancer with the lowest survival rates among all cancer types. Across all patients with pancreatic cancer, relative 5-year survival is 8% and is less than 3% for those with advanced disease.2 The median survival for patients in end-stage of the disease is approximately 3 months. There are two main types of pancreatic cancer - adenocarcinomas, which accounts for approximately 90% of all pancreatic cancer, and neuroendocrine tumors. Pancreatic cancer is relatively uncommon with new cases accounting for only 2.1% of all newly diagnosed cancers. However, pancreatic cancer is the fourth most common cause of cancer death for men and women in the United States.  

About SM-88
SM-88 is an oral investigational modified proprietary tyrosine derivative that is believed to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events.

About Tyme Technologies
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cancer cell death through oxidative stress and exposure to the body’s natural immune system. For more information, visit www.tymeinc.com. Follow us on social media: @tyme_Inc, LinkedIn, Instagram, Facebook and YouTube.

Forward-Looking Statements/Disclosure Notice
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidates including SM-88 and TYME- 18 and their clinical potential and non-toxic safety profiles, our drug development plans and strategies, ongoing and planned clinical trials, preliminary data results and the therapeutic design and mechanisms of our drug candidates; and readers can identify forward-looking statements by sentences or passages involving the use of terms such as “believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” or “anticipates,” and similar words including their use in the negative or by discussions of future matters such as the cost of development and potential commercialization of our lead drug candidate and of other new products, expected releases of interim or final data from our clinical trials, possible collaborations, the timing, scope and objectives of our ongoing and planned clinical trials and other statements that are not historical. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME’s control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, that the information is of a preliminary nature and may be subject to change; uncertainties inherent in the cost and outcomes of research and development, including the cost and availability of acceptable-quality clinical supply and the ability to achieve adequate clinical study design and start and completion dates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final data from any clinical trials may differ from prior or preliminary study data; final results of additional clinical trials that may be different from the preliminary data analysis and may not support further clinical development; that past reported data are not necessarily predictive of future patient or clinical data outcomes; whether and when any applications or other submissions for SM-88 may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88; the ability of TYME and its collaborators to develop and realize collaborative synergies; competitive developments; and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on June 12, 2019, as well as subsequent reports we file from time to time with the U.S. Securities and Exchange Commission available at www.sec.gov.

The information contained in this press release is as of its release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.  

For Investor Relations & Media Inquiries:
Contact:
1-212- 461-2315
investorrelations@tymeinc.com
media@tymeinc.com